14 min
October 2023 Editor’s Choice: OS updates for Imagyn50 Listen to Gynecologic Oncology
-
- Science
Editor’s Choice Paper:
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center
Editor’s Choice Paper:
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center
14 min